Aron Rose, MD

Research has focused primarily upon identification, medical and surgical treatment options for cataract and glaucoma, the two most common blinding conditions in the world.

Investigator: Open Label One Year Long Study to Evaluate the Long-Term Efficasy, Safety, and Acceptability of 2% Pilasite BID, 1992 Insite Vision.

Investigator: Three Month Study to Compare the Efficacy, Safety, and Tolerability of 0.1% Betasite and 0.5% Betasite to 0.5% Betagan BID in Subjects with Open Angle Glaucoma or Ocular Hypertension, 1992, Insite Vision.

Investigator: Long-Term Safety and Ocular Hypotensive Efficasy of Brimonidine Tartrate

0.2% in Subjects with Open Angle Glaucoma or Ocular Hypertension, 1993 Allergan.

Investigator: A Multi-Center, Randomized, Double-Blind, Parallel Clinical Study to Evaluate the Safety and Efficasy of Metipranolol 0.1% / Pilocarpine 2% BID, Metipranolol 0.3% / Pilocarpine 2% BID, Metipranolol 0.3% BID and Pilocarpine 2% QID for 12 Weeks in the Treatment of Patients with Ocular Hypertension or Glaucoma with Open Iridocorneal Angles, 1995 Bausch & Lomb.

Investigator: A Vehicle Controlled Study Evaluating the Ocular Safety and Efficasy of Ketorolac Tromethamine 0.5% Ophthalmic Solution in Subjects with Inflammation Following Cataract Surgery, 1995 Allergan.

Investigator: A Controlled Double-Masked, Two Period Crossover Study Comparing the Efficasy and Tolerability of 0.5% Timolol Maleate Gel Froming Solution QD vs. 0.5% Levobunolol Hydrochloride BID in Patients with Open Angle Glaucoma or Ocular Hypertension, 1996 Merck.

Investigator: A Controlled Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficasy of Dorzolamide Hydrochloride Ophthalmic Solution 2% in the Prophylaxis of Elevated Intraocular Pressure After Anterior Segment Laser Surgery, 1996 Merck.

Investigator: A Twelve Month Triple Masked Parallel Group Primary Therapy Study of AL-6221 .00015% and AL-6221 .0004% Compared to Timoptic 0.5% and Xalatan .005% in Patients with Open Angle Glaucoma or Ocular Hypertension, 1997-8 Alcon

Investigator: Three Month Study of the Evaluation of Xalatan When Used as Adjunctive Therapy to Betoptic S Ophthalmic Suspension 0.25% or Timoptic Ophthalmic Solution 0.5%, 1998-9 Alcon

Investigator: Safety and Efficasy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Twice Daily Compared With 0.5% Timolol Twice Daily or Alphagan Three Times Daily in Patients With Glaucoma or Ocular Hypertension, 2000-2001 Allergan

Investigator: A 48-Month, Mulit-Center, Randomized, Double-Masked, Placebo-Controlled, Clinical Study to Evaluate the Effectiveness and Safety of Oral Memantine in Daily Doses of 20 mg and 10 mg in Patients with Chronic Open-Angle Glaucoma at Risk for Glaucomatous Progression, 2000- 2007

Investigator: Safety and Efficacy of Phacoemulsification: Comparison of Sovereign with Whitestar and Legacy with Advantec and NeoSonix 12/02-4/03

Investigator: Comparative Clinical Trial of Ultrasound Phacoemulsification with and without WhiteStar System 2003

Investigator: Clinical Evaluation of a Lightweight Handpiece for the Sovereign Phacoemulsification System, 2003-2004

Principal Investigator: Thermal Imaging Study Comparing Phacoemulsification with the Sovereign WhiteStar System to the Legacy with AdvanTec and NeoSoniX System. 2004-2005

Investigator: Nepafenac Ophthamlic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery. 2005

Principal Investigator: Comparison of Post Operative Intraocular Inflammation After Standard Cataract Surgery With Either the AMO Sovereign WhiteStar ICE or the Alcon Infinity Phacoemulsification System. 2006-2007

Principal Investigator: Clinical Evaluation of a Modified Light Transmission Tecnis Acrylic Intraocular Lens, 2007 - 2009

Principal Investigator: Clinical Evaluation of a New Viscoelastic for Cataract Surgery, 2009-2010